Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390051 | 0.85 | GPR119 (0.71) | GPR119CYP2C9 | |
| SCHEMBL4765631 | 0.79 | GPR119 (0.56) | GPR119FLT3CDK2CDK6SCN9A | |
| SCHEMBL389552 | 0.78 | GPR119 (0.75) | GPR119CYP2C9 | |
| SCHEMBL1445594 | 0.77 | GPR119 (0.40) | GPR119CYP2C9 | |
| SCHEMBL386264 | 0.75 | GPR119 (0.55) | GPR119 | |
| SCHEMBL389519 | 0.74 | GPR119 (0.70) | GPR119CYP2C9 | |
| SCHEMBL386787 | 0.74 | GPR119 (0.80) | GPR119CYP2C9 | |
| SCHEMBL391379 | 0.73 | GPR119 (0.69) | GPR119CYP2C9 | |
| SCHEMBL390621 | 0.73 | GPR119 (0.68) | GPR119CYP2C9 | |
| SCHEMBL391698 | 0.73 | GPR119 (0.68) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |